Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 175 results
August 2016
-
Media ReleaseFDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseasesErelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's…
-
Media ReleaseSix leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of ImmunologyThe Basic Immunology Prize is awarded to John Kappler, Philippa Marrack and Harald von Boehmer for demonstrating that the ability of the immune system to discriminate "self" from "non-self" is…
July 2016
-
Media ReleaseSandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseasesCommittee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
-
Media ReleaseNew data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator productThe EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the…
June 2016
-
Media ReleaseNew data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator productsSandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
-
Media ReleaseNovartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
May 2016
-
Media ReleaseSandoz' biosimilar rituximab regulatory submission accepted by European Medicines AgencySandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label…
-
Media ReleaseNovartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of NovartisPaul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the…
-
Media ReleaseNovartis renforce la division Pharmaceuticals par la création de deux unités d'affaires, Novartis Pharmaceuticals et Novartis Oncology, et nomme de nouveaux dirigeants à son Comité de directionPaul Hudson devient CEO de Novartis Pharmaceuticals et Bruno Strigini devient CEO de Novartis Oncology ; David Epstein quitte Novartis Paul Hudson et Bruno Strigini sont nommés au Comité…
Pagination
- ‹ Previous page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- › Next page